All Oncology News

The FDA issued a reminder to increase awareness regarding updated capecitabine and 5-FU labels to highlight DPD deficiency risks.

Part 2 of the ongoing phase 2/3 HARBOR study is evaluating elenestinib in patients with indolent systemic mastocytosis.

Real-world data confirm the importance of tumor debulking with bridging therapy to reduce the risk of parkinsonism and NRM with cilta-cel in myeloma.

Ustekinumab plus prophylaxis did not reduce acute GVHD in patients who underwent HCT from matched unrelated donors.

No serious adverse effects were observed with TRX103 in patients with hematologic malignancies undergoing HLA-mismatched HCT.

The FDA-approved drug abatacept may improve treatment responses and prevent some immune AEs associated with CAR T-cell therapy.

Prophylactic dexamethasone did not reduce the risk of developing DNT, nor the severity of DNT presentation, in cilta cel–treated myeloma with high ALC.

Mabel Mardones, MD, discusses implications of data for Dato-DXd and sacituzumab govitecan in frontline metastatic triple-negative breast cancer.

Acalabrutinib yielded durable organ-specific responses and a manageable safety profile in patients with steroid-refractory chronic graft-vs-host disease.

Jill Gilbert, MD, offers a primer for hematology/oncology fellows ahead of the busy 2026 meeting season.

Real-world enfortumab vedotin dose reductions reduced treatment interruptions without significantly affecting OS in advanced urothelial carcinoma.

Pelareorep has received FDA fast track designation in combination with SOC bevacizumab and FOLFIRI in the second line for KRAS-mutant MSS mCRC.

MD Anderson data scientist Iakovos Toumazis, PhD, will further IDSO's goal to bring data science to inform decision-making for cancer control and public health.

Northwell’s Louis Potters, MD, discusses how treatment directives improve safety, consistency, and equity in cancer care in honor of World Cancer Day.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2026.

Sandip P. Patel, MD, discusses how AI can be used to improve clinical trial design and accrual.

Ryan D. Chow, MD, PhD, Ronac Mamtani, MD, MSCE, and Ramy Sedhom, MD, spotlight a real-world analysis of upfront enfortumab vedotin dose reduction in bladder cancer.

The FDA granted priority review to Dato-DXd for patients with first-line unresectable or metastatic TNBC who are not eligible to receive immunotherapy.

Tagraxofusp was well tolerated and yielded modest efficacy signals as monotherapy in myelofibrosis.

PATINA shows palbociclib added to anti-HER2 plus endocrine maintenance prolongs progression-free survival by 15+ months in HR+, HER2+ metastatic breast cancer.

Maurie Markman, MD, discusses the role of the individual vs the multidisciplinary team in cancer care.

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

Ahead of the 2026 Transplantation & Cellular Therapy Meetings, experts preview data on CAR T-cell therapy efficacy, donor access, and toxicity mitigation.

PRV211 was safe with no SAEs, systemic toxicities, or DLTs for the treatment of patients with invasive oral cavity cancer.

Mayo Clinic Comprehensive Cancer Center is expanding surgical options for patients undergoing treatment or risk-reducing procedures for breast cancer.

Real-world, head-to-head data show an improvement in OS with apalutamide plus ADT vs darolutamide plus ADT without docetaxel in mCSPC.

An NDA for zanzalintinib plus atezolizumab in pretreated metastatic colorectal cancer is under review by the FDA.

Marc J. Braunstein, MD, PhD, details the significance of the FDA approval of daratumumab plus VRd in transplant-ineligible, newly diagnosed myeloma.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

Fangfang Yan, PhD, discusses findings from a multi-omic analysis that identified mechanisms of pirtobrutinib resistance in mantle cell lymphoma.